Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

(2021) Xiaoying Shen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

(2021) Shabir A. Madhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant

(2021) Vivek Shinde et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

(2021) Catherine J. Reynolds et al.   SCIENCE

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

(2021) Jake A. Ruddy et al.   AIDS

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

(2021) Itzchak Levy et al.   CLINICAL MICROBIOLOGY AND INFECTION

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

(2021) Galit Alter et al.   NATURE

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine

(2021) Paul T. Heath et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study

(2021) Waasila Jassat et al.   Lancet HIV

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

(2021) John Frater et al.   Lancet HIV

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

(2021) Shabir A Madhi et al.   Lancet HIV

Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV

(2021) Zhengchao Lv et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico

(2021) Lisa M. Dunkle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

(2021) Neil Formica et al.   PLOS MEDICINE

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

(2020) Andrew Boulle et al.   CLINICAL INFECTIOUS DISEASES

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

(2020) Cheryl Keech et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

(2020) Krishnan Bhaskaran et al.   Lancet HIV

Influenza-Related Mortality Among Adults Aged 25–54 Years With AIDS in South Africa and the United States of America

(2012) Cheryl Cohen et al.   CLINICAL INFECTIOUS DISEASES

Persistent High Burden of Invasive Pneumococcal Disease in South African HIV-Infected Adults in the Era of an Antiretroviral Treatment Program

(2011) Marta C. Nunes et al.   PLoS One